University of Strathclyde - Superbug kryptonite

April 15, 2010

A Scottish research company is designing a new generation of antibiotics using academic expertise to combat drug-resistant bacteria such as the hospital "superbug" methicillin-resistant Staphylococcus aureus (MRSA). MGB Biopharma is to commercialise a new class of antibacterial product based on University of Strathclyde research. About £2 million in funding has been secured for the project, which uses technology licensed from Strathclyde. So far it has shown positive results in combating gram-negative and gram-positive bacteria, including MRSA.

Please login or register to read this article

Register to continue

Get a month's unlimited access to THE content online. Just register and complete your career summary.

Registration is free and only takes a moment. Once registered you can read a total of 3 articles each month, plus:

  • Sign up for the editor's highlights
  • Receive World University Rankings news first
  • Get job alerts, shortlist jobs and save job searches
  • Participate in reader discussions and post comments

Have your say

Log in or register to post comments